Loading...
India's ondansetron imports from GERMANY total $5.2K across 8 shipments from 4 foreign suppliers. MERCKLE GMBH leads with $2.4K in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for ondansetron — a diversified sourcing base with multiple active suppliers from GERMANY.
MERCKLE GMBH is the leading Ondansetron supplier from GERMANY to India, with import value of $2.4K across 4 shipments. The top 5 suppliers — MERCKLE GMBH, PRIVAPOSERVICES GMBH, RX SOLUTION LIMITED, Merckle Gmbh — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MERCKLE GMBH | $2.4K | 4 | 45.9% |
| 2 | PRIVAPOSERVICES GMBH | $1.9K | 1 | 36.5% |
| 3 | RX SOLUTION LIMITED | $841 | 2 | 16.2% |
| 4 | Merckle Gmbh | $76 | 1 | 1.5% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED | $2.4K | 4 | 45.9% |
| 2 | AJANTA PHARMA LIMITED | $1.9K | 1 | 36.5% |
| 3 | AGIO PHARMACEUTICALS LIMITED |
GERMANY → India trade corridor intelligence
The Germany to India trade corridor for pharmaceutical imports is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year. The exchange rate between the Euro and the Indian Rupee has shown slight fluctuations but remains within a manageable range for importers.
India's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing, potentially reducing reliance on imports of finished pharmaceutical formulations. However, the demand for specific formulations, such as certain Ondansetron dosage forms, may continue to necessitate imports. Import substitution policies are being evaluated to balance domestic production growth with the need for high-quality imported products.
India and Germany maintain strong trade relations, with ongoing discussions to enhance pharmaceutical trade. Negotiations focus on mutual recognition of Good Manufacturing Practices (GMP), facilitating smoother import processes. Both countries are committed to adhering to World Trade Organization (WTO) regulations, ensuring fair and transparent trade practices.
| $841 |
| 2 |
| 16.2% |
| 4 | TEVAPHARM INDIA PRIVATE LIMITED | $76 | 1 | 1.5% |
The estimated landed cost for importing finished pharmaceutical formulations containing Ondansetron from Germany to India is calculated as follows:
1. FOB Price: The cost of the goods as agreed upon between the buyer and seller.
2. Freight and Insurance: Costs associated with shipping and insuring the goods to the port of entry in India.
3. Basic Customs Duty (BCD): 10% of the assessable value.
4. Social Welfare Surcharge (SWS): 10% of the BCD.
5. Integrated Goods and Services Tax (IGST): 12% of the assessable value plus BCD and SWS.
6. Port Handling and Customs Broker Charges: Additional fees for handling and clearing the goods through customs.
These components contribute to the total landed cost, which importers should consider when evaluating the financial viability of importing from Germany.
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Ondansetron into India, the following regulatory requirements must be met:
1. Import License: Importers must obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. Product Registration: The product must be registered with the Central Drugs Standard Control Organisation (CDSCO). This involves submitting Form 40 or 41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Free Sale Certificate, and manufacturing license.
3. Approval Process: The CDSCO evaluates the application, which may take several months. Upon approval, an Import License is issued, authorizing the import of the specific formulation.
4. No Objection Certificate (NOC): Depending on the product, an NOC from the State Drug Controller may be required.
The entire process can take approximately 6 to 12 months, depending on the completeness of the application and the regulatory workload.
Imported pharmaceutical formulations containing Ondansetron must undergo quality testing to ensure compliance with Indian standards:
1. Testing Laboratories: Samples are sent to CDSCO-approved laboratories for analysis.
2. Batch Certification: Each batch must be accompanied by a Certificate of Analysis (CoA) from the manufacturer, detailing the product's composition and quality parameters.
3. Stability Data: Manufacturers must provide stability data demonstrating the product's shelf-life under Indian climatic conditions, adhering to ICH Zone IV guidelines.
4. Pharmacopoeia Standards: The product must conform to the standards set by the Indian Pharmacopoeia.
Port inspections by customs drug inspectors are conducted to verify compliance with these requirements.
Recent developments in India's import policies affecting finished pharmaceutical formulations containing Ondansetron include:
1. Regulatory Updates: The CDSCO has streamlined the approval process for certain pharmaceutical imports, reducing processing times.
2. PLI Scheme Impact: The Production Linked Incentive (PLI) scheme has incentivized domestic production, potentially affecting the volume of imports.
3. Bilateral Agreements: India and Germany have engaged in discussions to facilitate smoother trade in pharmaceutical products, including mutual recognition of Good Manufacturing Practices (GMP).
These changes aim to balance the promotion of domestic manufacturing with the need for high-quality imported formulations.
Market demand, customs duty structure, and competitive landscape · Import duty: 10%
India imports finished Ondansetron formulations to meet the demand for specific dosage forms not produced domestically, such as certain tablet strengths and injection forms. The domestic market for Ondansetron is substantial, with a total export value of $121.0 million across 537 exporters to 157 countries. However, domestic production may not fully satisfy the demand for all formulations, leading to reliance on imports.
The total landed cost for importing finished pharmaceutical formulations containing Ondansetron into India includes:
1. Basic Customs Duty (BCD): 10% of the assessable value.
2. Social Welfare Surcharge (SWS): 10% of the BCD.
3. Integrated Goods and Services Tax (IGST): 12% of the assessable value plus BCD and SWS.
Additional charges may include port handling fees, customs broker charges, and other applicable taxes.
India sources finished Ondansetron formulations from Germany due to several factors:
1. Quality Assurance: German manufacturers are known for high-quality standards and compliance with international regulations.
2. Specialized Formulations: Germany offers specific formulations and dosage forms not readily available from other suppliers.
3. Regulatory Compliance: German products often meet the stringent requirements of the CDSCO, facilitating smoother import processes.
While other countries like China and the USA also supply Ondansetron formulations, Germany's reputation for quality and reliability makes it a preferred source for Indian importers.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports finished Ondansetron formulations from Germany due to the availability of specific dosage forms and formulations not produced domestically. German manufacturers offer high-quality products that meet the stringent requirements of the CDSCO, ensuring compliance and safety. The reputation of German pharmaceutical companies for reliability and adherence to international standards makes them a preferred source for Indian importers.
When compared to other sources like China and the USA, Germany offers several advantages:
1. Quality Assurance: German products are known for high-quality standards and compliance with international regulations.
2. Regulatory Compliance: German manufacturers often meet the stringent requirements of the CDSCO, facilitating smoother import processes.
3. Product Range: Germany offers specific formulations and dosage forms not readily available from other suppliers.
While other countries may offer competitive pricing, Germany's reputation for quality and reliability makes it a preferred source for Indian importers.
Importing finished pharmaceutical formulations from Germany involves certain risks:
1. Single-Source Risk: Relying on a single supplier can lead to supply chain disruptions in case of unforeseen events.
2. Currency Fluctuations
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Ondansetron suppliers from GERMANY to India include MERCKLE GMBH, PRIVAPOSERVICES GMBH, RX SOLUTION LIMITED. The leading supplier is MERCKLE GMBH with import value of $2.4K USD across 4 shipments. India imported Ondansetron worth $5.2K USD from GERMANY in total across 8 shipments.
India imported Ondansetron worth $5.2K USD from GERMANY across 8 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Ondansetron sourced from GERMANY include ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED, AJANTA PHARMA LIMITED, AGIO PHARMACEUTICALS LIMITED. The largest buyer is ACTAVIS PHARMA DEVELOPMENT CENTRE PRIVATE LIMITED with $2.4K in imports across 4 shipments.
The total value of Ondansetron imports from GERMANY to India is $5.2K USD, across 8 shipments and 4 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
8 Verified Shipments
4 suppliers, 4 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists